Laboratory bench filled with scientific equipment

A laboratory bench with scientific equipment. Source: Adam Bezer/Unsplash, Unsplash License

Alachua-based Axogen grew Q3 2026 revenue 26% to $75.8 million, raised 2026 guidance to $290 million, closed BioCircuit and ended September with no debt.

Quick Answer: Axogen, the Alachua-based nerve-repair company, reported third-quarter 2026 revenue of $75.8 million, up 26.2% from a year earlier, with net income of $2.3 million. It raised its full-year revenue guidance to at least $290 million, which includes the newly acquired BioCircuit Technologies. It also ended September with about $350 million in cash and investments and no long-term debt.

Axogen Inc. has headquarters in a leased office suite on Progress Boulevard in the City of Alachua. For most of its history it has been a growth story that did not turn a consistent profit. Its third quarter of 2026 changed parts of that picture. Revenue growth accelerated from the second quarter. The company stayed profitable on a GAAP basis. It paid off its term loan. A September stock sale funded a $200 million acquisition and still left more than $300 million on the balance sheet.

Axogen released the results on October 28, 2026, alongside its Form 10-Q. Figures below are as of September 30, 2026, unless noted otherwise.

How much revenue did Axogen earn in Q3 2026?

Revenue for the quarter ended September 30, 2026, was $75.8 million, up from $60.1 million in the third quarter of 2025. That is an increase of $15.75 million, or 26.2%. The 10-Q attributes the growth mainly to higher unit volume, with price changes also contributing. Revenue for the first nine months was $207.0 million, up 25.2% from $165.3 million.

Second-quarter revenue was $69.7 million, up 23.1%. Subtracting the second and third quarters from the nine-month total puts first-quarter revenue at roughly $61.5 million.

Metric Q3 2026 Q3 2025 Change
Revenue $75.8M $60.1M +26.2%
Gross profit $56.7M $46.0M +23.3%
Gross margin 74.8% 76.6% -1.8 pts
Income from operations $1.0M $1.9M -50%
Net income $2.3M ($0.04/sh) $0.7M ($0.01/sh) +$1.6M
Adjusted net income $13.1M ($0.21/sh) $6.1M ($0.12/sh) More than doubled
Adjusted EBITDA $13.4M (17.7%) $9.2M (15.4%) +$4.2M

Why did net income rise while operating income fell?

Operating income fell from $1.9 million to $955,000 because total costs and expenses grew 26.5%, slightly faster than revenue. Net income still more than tripled because of two changes below the operating line. Investment income rose to $1.4 million from $319,000 as the company’s cash balance grew. Interest expense fell to about $1,000 from $1.76 million because the company no longer carries a term loan.

The nine-month results show the cost of paying down that debt. Axogen reported a net loss of $18.8 million, or $0.35 per share, for the first nine months of 2026. That total includes a one-time $16.8 million loss on extinguishment of debt recorded in the first quarter. Without that charge, the nine-month loss would have been about $1.9 million.

Where did Axogen’s operating costs go?

Sales and marketing remained the largest expense at $30.4 million, up 18.2%. Research and development was $9.0 million, up 18.3%. General and administrative expense rose 51.9% to $16.5 million. According to the 10-Q, that increase included about $2.0 million of transaction and integration costs for the BioCircuit deal. It also reflected higher compensation, up $4.7 million, and higher stock-based compensation, up $3.4 million. The company said the stock-based compensation increase came from performance share units that vested above target.

The sales force is still growing. On the earnings call, CEO Michael Dale said the breast business had 31 sales representatives and 3 regional directors, 10 more than at the start of the year. The extremities, oral maxillofacial and head and neck team had 132 representatives and 15 regional directors, 15 more than at the start of the year. CFO Lindsey Hartley said hiring would continue into 2027.

Why did Axogen’s gross margin slip?

Gross margin was 74.8% in the third quarter, down from 76.6% a year earlier but up from 72.7% in the second quarter. The 10-Q attributes the year-over-year decline to higher product costs, partly offset by lower inventory write-offs. On the call, Hartley said product cost added about 3 percentage points of pressure and lower write-offs offset about 1.2 points.

The underlying cause is a change in product mix. The breast reconstruction business is growing fastest, and those procedures use longer Avance grafts. Hartley said fourth-quarter gross margin should fall again to slightly below the second-quarter level. One reason is a possible inventory step-up from BioCircuit purchase accounting. She also said 2027 gross margin should be broadly in line with 2026.

What is Axogen’s 2026 guidance?

Axogen raised its revenue outlook again. In July, management expected full-year revenue of at least $279 million, or at least 24% growth. The October release raised the target to at least $290 million, or at least 29% growth, including at least $7 million from BioCircuit in the fourth quarter. Excluding BioCircuit, the company expects organic revenue of at least $283 million, or growth of at least 26%. That is $4 million above the July figure. Based on these growth rates, 2025 revenue was roughly $225 million.

2026 guidance item July 29, 2026 October 28, 2026
Total revenue At least $279M (24%+ growth) At least $290M (29%+ growth)
Organic revenue (excl. BioCircuit) Not separated At least $283M (26%+ growth)
BioCircuit contribution Not included At least $7M
Gross margin At least 73% At least 73%
Free cash flow Positive Positive

Nine-month revenue was $207.0 million, so reaching the $290 million floor requires about $83 million in the fourth quarter. That would be about $7 million more than the third quarter, roughly the amount Axogen expects BioCircuit to contribute. Through September, Axogen generated $25.3 million in operating cash flow and spent $5.1 million on capital expenditures, leaving $18.9 million in free cash flow., compared with negative $5.9 million a year earlier.

Which markets are driving Axogen’s growth?

Axogen sells into three main markets: extremities (nerve injuries in the hands and limbs), oral maxillofacial and head and neck surgery, and breast reconstruction. The 10-Q describes nine-month growth as broad-based across all three. On the call, Hartley said breast revenue grew more than 60% in the third quarter, while Dale’s prepared remarks described breast growth as more than 50%. Axogen reported about 485 active breast accounts and about 590 active breast surgeons.

The extremities, oral maxillofacial and head and neck businesses grew 10.7% combined. Dale said extremities growth would have been about 15% after adjusting for initial inventory stocking at accounts a year earlier. He expects that business to grow at a high-single-digit to low-double-digit rate over time.

The 2025 annual report sizes the U.S. peripheral nerve injury market at $5.6 billion or more, plus about $754 million in urology.

What is happening with prostate surgery?

Urology is Axogen’s next target. The company said positive clinical study outcomes support beginning market development in prostate surgery in 2027. On the call, Dale said more than 220 patients had been treated with Avance at 15 clinical development sites. Of the 117 patients with at least six months of follow-up, about 80% reported better-than-expected recovery of erectile function. More than 95% reached pad-free continence at or above expected levels, and no graft-related complications were reported. Prostate is not included in current guidance; financial details are expected at a March 2027 investor day.

What is the FDA status of the Avance nerve graft?

Avance is a processed human nerve allograft that surgeons use to bridge gaps in damaged peripheral nerves. It has been sold since 2007. For most of that time it was regulated as a human tissue product. On December 3, 2025, Axogen announced FDA approval of its Biologics License Application, filed in September 2024, which moved Avance into the biologics framework. The licensed product carries the name Avance (acellular nerve allograft-arwx).

The approval covers adults and children as young as one month with sensory, mixed and motor peripheral nerve gaps. Some indications received accelerated approval: sensory gaps longer than 25 millimeters, mixed nerves and motor nerves. The 10-Q states that continued approval for those indications depends on confirmatory studies that verify and describe the clinical benefit.

The 2025 annual report says Axogen expects 12 years of U.S. protection against biosimilar competition, measured from the approval date. The same report said about 65% of commercially insured U.S. patients had coverage for procedures using Axogen products. In the October release, the company put commercial payer coverage for Avance at about 96% of covered lives and cited positive decisions from Elevance and Aetna.

What did Axogen buy with BioCircuit?

On October 1, 2026, Axogen completed its purchase of BioCircuit Technologies Inc., a privately held Georgia medical device company that developed NerveTape. The base price was $200 million in cash, subject to adjustments. Transaction expenses were $1.9 million in the third quarter, and the 10-Q says the company expects about $5 million more in the fourth quarter.

NerveTape is used for direct repair, in which the two ends of a cut nerve are joined without a graft. Dale said direct repair accounts for 40% to 50% of transected nerve procedures and called NerveTape the sixth product in the company’s nerve repair lineup. According to the call, BioCircuit sold to about 400 accounts through roughly 50 distributor representatives. Axogen’s direct sales organization covers nearly 3,000 accounts.

How did Axogen fund the deal and pay off its debt?

Axogen made two stock offerings in 2026. In January, it sold 4.6 million shares at $31.00 per share for net proceeds of $133.3 million. On January 28, it used $69.7 million, including a make-whole payment, to repay its credit facility with Oberland Capital and affiliates.

In September, Axogen sold 5,646,500 shares at $42.50 per share, including the underwriters’ option, for net proceeds of $225.0 million. Shares outstanding increased to 59.7 million at September 30 from 47.2 million at the end of 2025, which dilutes existing shareholders’ ownership. Shareholders’ equity rose to $496.1 million from $128.8 million.

Balance sheet item Sept. 30, 2026 Dec. 31, 2025
Cash and cash equivalents $328.9M $35.5M
Investments $19.2M $6.0M
Long-term debt, net $0 $48.4M
Inventory $49.1M $42.4M
Total assets $550.3M $221.7M
Total liabilities $54.2M $92.8M

About $200 million of that cash went to BioCircuit on October 1, leaving roughly $150 million. Management says cash and product sales will fund operations for at least the next 12 months. The current ratio at quarter-end was 12.0.

What does Axogen operate in Alachua and elsewhere?

Axogen’s principal executive offices are at 13631 Progress Boulevard in Alachua. The company leases about 19,000 square feet there and extended that lease in February 2026 through December 31, 2031. Avance is processed and packaged at the Axogen Processing Center in Vandalia, Ohio, near Dayton. The building covers 107,000 square feet on about 8.5 acres. Axogen also uses a third-party facility in Dayton for its Avive+ Soft Tissue Matrix. The Axoguard product line is made by contract manufacturer Evergen in West Lafayette, Indiana.

The Ohio facility comes with obligations. State and local economic development grants worth up to about $2.7 million, including $1.25 million in cash, helped offset its costs. The 10-Q says about $950,000 could be clawed back if minimum job and payroll requirements are not maintained through December 31, 2026.

How does Axogen fit Alachua’s life-sciences cluster?

The City of Alachua is also home to UF Innovate’s Sid Martin Biotech incubator in Progress Park. The University of Florida says the 32,546-square-foot facility has 25 wet labs and 13 active biotech companies. Axogen, with $550 million in total assets, is a commercial-stage counterpart to those early-stage firms.

What should Central Florida business watchers track next?

There are four points to watch. First is whether fourth-quarter revenue reaches about $83 million, the amount implied by guidance. Second is how far gross margin falls as BioCircuit purchase accounting and breast product mix weigh on results. Third is the progress of confirmatory studies tied to Avance’s accelerated-approval indications. Fourth is the urology plan Axogen expects to detail in March 2027, when it also plans to give formal 2027 guidance.

Frequently Asked Questions

Is Axogen profitable?

Axogen earned GAAP net income of $2.3 million in the third quarter of 2026. For the first nine months, it reported a net loss of $18.8 million, mostly because of a $16.8 million one-time loss on early debt repayment.

Is Avance FDA approved?

Yes. The FDA approved Axogen’s Biologics License Application for Avance on December 3, 2025. Some indications received accelerated approval, and continued approval for them depends on confirmatory studies.

What is NerveTape?

NerveTape is a direct nerve repair product developed by BioCircuit Technologies of Georgia. Axogen bought BioCircuit for a $200 million base cash price on October 1, 2026.

What is Axogen’s 2026 revenue forecast?

Axogen expects revenue of at least $290 million, including at least $7 million from BioCircuit, with gross margin of at least 73% and positive free cash flow for the full year.

Does Axogen have debt?

No long-term debt was outstanding at September 30, 2026. Axogen repaid its Oberland Capital credit facility for $69.7 million in January 2026.

Sources and Further Reading

  1. Axogen, Inc. Reports Third Quarter 2026 Financial Results (Exhibit 99.1 to Form 8-K) — U.S. Securities and Exchange Commission / Axogen, Inc.
  2. Axogen, Inc. Form 10-Q for the quarter ended September 30, 2026 — U.S. Securities and Exchange Commission
  3. Axogen, Inc. Reports Second Quarter 2026 Financial Results (Exhibit 99.1 to Form 8-K) — U.S. Securities and Exchange Commission / Axogen, Inc.
  4. Axogen Announces FDA Approval of Biologics License Application for AVANCE (Exhibit 99.1 to Form 8-K, December 3, 2025) — U.S. Securities and Exchange Commission / Axogen, Inc.
  5. Axogen, Inc. Form 10-K for fiscal year 2025 — U.S. Securities and Exchange Commission
  6. Axogen Q3 2026 Earnings Call Transcript — TradingKey
  7. Sid Martin Biotech facility overview — UF Innovate, University of Florida

About The Author